Enzychem Lifesciences Corporation (183490.KQ)
KRW 1329.0
(-2.71%)
KRW 1329.0
(-2.71%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 76.03 Billion KRW | 185.46% |
| 2022 | 26.63 Billion KRW | 15.94% |
| 2021 | 22.97 Billion KRW | -11.01% |
| 2020 | 25.81 Billion KRW | -17.96% |
| 2019 | 31.46 Billion KRW | 1.4% |
| 2018 | 31.03 Billion KRW | 18.75% |
| 2017 | 26.13 Billion KRW | 19.68% |
| 2016 | 21.83 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 22.24 Billion KRW | -4.16% |
| 2024 Q2 | 19.6 Billion KRW | -11.87% |
| 2023 Q4 | 23.21 Billion KRW | 17.43% |
| 2023 Q1 | 15.63 Billion KRW | 135.18% |
| 2023 Q2 | 17.42 Billion KRW | 11.48% |
| 2023 FY | 76.03 Billion KRW | 185.46% |
| 2023 Q3 | 19.76 Billion KRW | 13.42% |
| 2022 Q2 | 7.58 Billion KRW | 11.83% |
| 2022 FY | 26.63 Billion KRW | 15.94% |
| 2022 Q4 | 6.64 Billion KRW | 18.08% |
| 2022 Q3 | 5.62 Billion KRW | -25.74% |
| 2022 Q1 | 6.77 Billion KRW | 4.44% |
| 2021 Q1 | 5.24 Billion KRW | 32.78% |
| 2021 FY | 22.97 Billion KRW | -11.01% |
| 2021 Q4 | 6.49 Billion KRW | 16.89% |
| 2021 Q3 | 5.55 Billion KRW | -2.31% |
| 2021 Q2 | 5.68 Billion KRW | 8.32% |
| 2020 Q4 | 3.95 Billion KRW | -10.35% |
| 2020 Q3 | 4.4 Billion KRW | -44.2% |
| 2020 Q1 | 9.55 Billion KRW | 12.19% |
| 2020 Q2 | 7.9 Billion KRW | -17.33% |
| 2020 FY | 25.81 Billion KRW | -17.96% |
| 2019 Q3 | 7.37 Billion KRW | -1.31% |
| 2019 Q1 | 8.1 Billion KRW | 7.84% |
| 2019 FY | 31.46 Billion KRW | 1.4% |
| 2019 Q4 | 8.51 Billion KRW | 15.5% |
| 2019 Q2 | 7.47 Billion KRW | -7.74% |
| 2018 FY | 31.03 Billion KRW | 18.75% |
| 2018 Q2 | 8.11 Billion KRW | 1.67% |
| 2018 Q4 | 7.51 Billion KRW | 1.25% |
| 2018 Q3 | 7.41 Billion KRW | -8.61% |
| 2018 Q1 | 7.98 Billion KRW | -12.13% |
| 2017 Q2 | 6.51 Billion KRW | 0.0% |
| 2017 FY | 26.13 Billion KRW | 19.68% |
| 2017 Q3 | 4.5 Billion KRW | -30.79% |
| 2017 Q4 | 9.08 Billion KRW | 101.52% |
| 2016 FY | 21.83 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 135.95 Billion KRW | 44.07% |
| CMG Pharmaceutical Co., Ltd. | 93.9 Billion KRW | 19.027% |
| Celltrion Pharm, Inc. | 388.79 Billion KRW | 80.442% |
| Huons Global Co., Ltd. | 758.37 Billion KRW | 89.974% |
| DongKook Pharmaceutical Co., Ltd. | 730.99 Billion KRW | 89.598% |
| Humedix Co., Ltd. | 152.27 Billion KRW | 50.064% |
| Boditech Med Inc. | 134.21 Billion KRW | 43.347% |
| EuBiologics Co., Ltd. | 69.36 Billion KRW | -9.62% |
| FutureChem Co.,Ltd | 13.96 Billion KRW | -444.379% |
| Huons Co., Ltd. | 552 Billion KRW | 86.225% |
| BNC Korea Co., Ltd. | 80.99 Billion KRW | 6.122% |
| AptaBio Therapeutics Inc. | 323.86 Million KRW | -23378.3% |